IRWD beat EPS expectations by 135.29%
Nov 16, 2025, 11:32 AM
0.00%
What does IRWD do
Ironwood Pharmaceuticals, based in Boston, develops GI products including LINZESS for IBS-C and CIC, and is advancing treatments like apraglutide for rare GI diseases and IW-3300 for visceral pain conditions. The company, which went public in 2010, employs 267 people.
Ironwood Pharmaceuticals (IRWD) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Ironwood Pharmaceuticals's actual EPS was $0.24, beating the estimate of $0.10 per share, resulting in a 135.29% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.